Disease activity score in 28 joints at 3 months after the initiation of biologic agent can be a predictive target for switching to the second biologic agent in patients with polyarticular juvenile idiopathic arthritis

Tomohiro KubotaDepartment of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan, Correspondence[email protected]

Hiroyuki ImanakaDepartment of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan,

Syuji TakeiDepartment of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ;Faculty of Medicine, School of Health Sciences, Kagoshima University, Kagoshima, Japan, and

Tsuyoshi YamatouDepartment of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan,

Yasuhito NeromeEducation Center for the Doctors in Remote Islands and Rural area, Graduate School of Medical and Dental Science, Kagoshima University, Kagoshima, Japan

Yuuichi YamasakiDepartment of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan,

Yukiko NonakaDepartment of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan,

Harumi AkaikeDepartment of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan,

Tomoko TakezakiDepartment of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan,

Yosihumi KawanoDepartment of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan,

show all

Abstract

Objective: To clarify polyarticular juvenile idiopathic arthritis (pJIA) patients who failed to maintain prolonged remission with the first biologic agent.

Methods: Fourteen pJIA patients were observed for 47.5 months (median) after initiating the first biologic agent.

Results: Eight maintained sustained clinical remission (median 47 months) with the first biologic agents, while the six switched to the second one due to lack of efficacy, thereafter. Receiver operating characteristic (ROC) analysis revealed that disease activity score in 28 joints (DAS28) of 2.37 at 3 months could distinguish between the two patient groups (p = 0.001).

Conclusion: pJIA patients with DAS28 >2.37 at 3 months of the initial biologic therapy may be considered to switch to the second biologics.

Keywords:

Supplementary material available online

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Disease activity score in 28 joints at 3 months after the initiation of biologic agent can be a predictive target for switching to the second biologic agent in patients with polyarticular juvenile idiopathic arthritis

Information for

Open access

Opportunities

Help and information

Disease activity score in 28 joints at 3 months after the initiation of biologic agent can be a predictive target for switching to the second biologic agent in patients with polyarticular juvenile idiopathic arthritis

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature